Open Access. Powered by Scholars. Published by Universities.®
Hematology/Oncology and Stem Cell Therapy
Adoptive immunotherapy; Axicabtagene ciloleucel; Lymphoma non-Hodgkin; Neoplasm recurrence; Salvage therapy; Response predictor
Articles 1 - 1 of 1
Full-Text Articles in Cancer Biology
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma, Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma, Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro
Hematology/Oncology and Stem Cell Therapy
Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtagene ciloleucel (axi-cel) at two Mayo Clinic centers between 2018 and 2020. We evaluated predictive factors, toxicities, and responses to salvage regimens after CAR T-cell therapy. Results: Thirty-four patients received axi-cel with a median length of hospitalization of 14 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 91% and 41% of patients, respectively. …